Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults

NCTNCT07240246 (opens ClinicalTrials.gov in a new tab)Other id1098/2025
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Names Glucagon, does not test it. It appears in the summary.

Overview

Status
Completed
Phase
Not applicable
Enrollment
40 participants (actual)
Sponsor
FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation · Other
Design
Randomized · Quadruple masking
Countries
1 country

Austria

Start
24 Oct 2025
Primary completion
11 Mar 2026
Completion
12 May 2026
First posted
20 Nov 2025
Last update posted
15 Jun 2026
Conditions
GLP-1 · Obesity &Amp; Overweight · Dietary Supplement

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202520262027
  1. N/A

    Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults

    NCT07240246

    24 Oct 2025 to 12 May 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are not suitable for all patients, and adherence can be limited. Dietary supplements that influence appetite and satiety may represent an alternative or complementary approach. This study will evaluate whether a dietary supplement containing plant extracts stimulates the intestinal incretin response. The primary focus is the effect on glucagon-like peptide-1 (GLP-1) secretion. Secondary outcomes include dipeptidyl peptidase-4 (DPP-4), gastric inhibitory peptide (GIP), and insulin, as well as measures of appetite, satiety, food intake, and anthropometrics. The trial is designed as a 12-week, double-blind, randomized, placebo-controlled parallel-group study in adults with overweight or obesity (BMI 25-40, age 18-50). Participants will receive either the dietary supplement or placebo. Blood samples will be collected at baseline and after 12 weeks, both fasting and following capsule intake and a standardized liquid meal. Anthropometric measurements and visual analog scales (VAS) for hunger and satiety will also be assessed.

Interventions

  • Intervention: Dietary Supplement with Plant ExtractsDietary supplement
  • PlaceboOther

Arms2

  • Active comparator

    Dietary Supplement

    Participants receive a dietary supplement: Capsule preparation containing hypromellose, calcium phosphate, inulin, yeast extract (Saccharomyces cerevisiae), bitter melon extract, green coffee bean extract, white mulberry extract, purslane extract, peppermint leaf extract, dandelion extract, green mate extract, zinc gluconate, ginger extract, biotin and yellow iron oxide (E172 - capsule colouring)

  • Placebo comparator

    Placebo

    Participants receive a capsule preparation containing hypromellose, calcium phosphate, inulin and yellow iron oxide (E172 - capsule colouring agent)

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. GLP-1 secretion

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks changes GLP-1 secretion (area under the curve (AUC) over 60 minutes) in overweight or obese subjects\* compared to the start of the study (AUC over 60 minutes).

Secondary outcomes(13)

  1. Intervention vs. Placebo

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks changes GLP-1, DPP-4, GIP, and insulin secretion (AUC over 60 min) in overweight or obese subjects\* compared to taking a placebo (AUC over 60 min).

  2. Liquid Meal

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks changes GLP-1, DPP-4, GIP, and insulin secretion (AUC over 60 min) in overweight or obese subjects\* after consuming a standardised liquid meal compared to intake at the start of the study (AUC over 60 min).

  3. Liquid Meal: Intervention vs. Placebo

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks changes GLP-1, DPP-4, GIP, and insulin secretion (AUC over 60 min) in overweight or obese subjects\* after consuming a standardised liquid meal compared to taking a placebo (AUC over 60 min).

  4. Body weight

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks leads to changes in body weight (kg).

  5. Body mass index (BMI) in kg/m²

    Time frame · 12 weeks

    Registry description

    BMI in kg/m² will be determined using weight (kg) and height (m). Taking the dietary supplement over a period of 12 weeks leads to changes in BMI.

  6. Abdominal Circumference

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement over a period of 12 weeks leads to changes in the abdominal circumference (cm).

  7. Waist to Hip Ratio

    Time frame · 12 weeks

    Registry description

    Taking the dietary supplement leads to changes in the waist-hip ratio (cm waist/cm hip = WHR).

  8. Changes in Control of Eating Questionnaire (CoEQ)

    Time frame · 12 weeks

    Registry description

    Participants report on their control of eating by answering the Control of Eating Questionnaire (CoEQ) with 19 questions. Rating on a horizontal, non-calibrated line of 10 cm, ranging from very low (0) to very high (10).

  9. Visual analog scale (VAS) to assess hunger

    Time frame · 12 weeks

    Registry description

    Visual analog scale (VAS) to assess hunger on a horizontal, non-calibrated line of 10 cm, ranging from not hungry at all (0) to very hungry (10)

  10. Visual analog scale (VAS) to assess satiation

    Time frame · 12 weeks

    Registry description

    Visual analog scale (VAS) to assess satiation (process that leads to the termination of eating) on a horizontal, non-calibrated line of 10 cm, ranging from completely empty (0) to cannot eat another bite (10)

  11. Visual analog scale (VAS) to assess desire to eat

    Time frame · 12 weeks

    Registry description

    Visual analog scale to assess desire to eat on a horizontal, non-calibrated line of 10 cm, ranging from very low (0) to very strong (10)

  12. Visual analog scale (VAS) to assess the amount that can be eaten right now

    Time frame · 12 weeks

    Registry description

    Visual analog scale to assess the amount that can be eaten right now on a horizontal, non-calibrated line of 10 cm, ranging from not at all (0) to a large amount (10)

  13. Visual analog scale (VAS) to assess satiety

    Time frame · 12 weeks

    Registry description

    Visual analog scale to assess satiety (feeling of fullness that persists after eating suppressing further energy intake) on a horizontal, non-calibrated line of 10 cm, ranging from not full at all (0) to totally full (10)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies5

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Review · 2025

What is the pipeline for future medications for obesity?

Melson et al. 2025International journal of obesity (2005)cited by 214

PMID 38302593PMC11971045DOI 10.1038/s41366-024-01473-yPUB-38302593

CC BY
Download PDF

Indexing hint: Randomized controlled trial · 2024

8 results

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.

Gabe et al. 2024Diabetes, obesity & metabolismcited by 36

PMID 39082206DOI 10.1111/dom.15802PUB-39082206

Full text at the publisher8 results
Publisher pageSee results (8)

More studies

3 studies on this page

PubMed tag: none · 2024

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

Gleason et al. 2024Journal of managed care & specialty pharmacycited by 165

PMID 38717042PMC11293763DOI 10.18553/jmcp.2024.23332PUB-38717042

Rights unknown
Source link

PubMed tag: none · 2023

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.

Stenlid et al. 2023Frontiers in endocrinologycited by 8

PMID 38027106PMC10646558DOI 10.3389/fendo.2023.1293093PUB-38027106

CC BY
Download PDF

Indexing hint: Review · 2021

Diets and drugs for weight loss and health in obesity - An update.

Aaseth et al. 2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapiecited by 112

PMID 34082399DOI 10.1016/j.biopha.2021.111789PUB-34082399

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 50 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Signing the consent form * BMI 25-40 kg/m² * Age 18-50 years Exclusion Criteria: * Known allergy to ingredients in the administered substances * Type 1 or 2 diabetes * Pregnancy * Breastfeeding mothers * Acute infectious disease * Renal insufficiency

PepBank is a research reference. Talk to a doctor before you use any peptide.